ALGS - Aligos Therapeutics and Xiamen Amoytop Biotech join hands for the treatment of liver diseases

2023-05-15 02:31:48 ET

Clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, Aligos Therapeutics ( NASDAQ: ALGS ) enters research and development collaboration with Xiamen Amoytop Biotech for the use of Aligos’ oligonucleotide platform

They will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights.

Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109M in development and sales milestone payments for licensed products as well as tiered royalties on net sales.

For further details see: